Current Opinion in Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: March 27, 2025
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown. This aims consolidate existing evidence on GLP-1RA conditions such diabetic retinopathy (DR), nonarteritic ischemic optic neuropathy (NAION), glaucoma, age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH), dry eye disease (DED). Recent findings The effect DR is controversial likely linked rapid correction hemoglobin A1c levels. may be associated increased risk NAION, although mechanism remains elusive. Protective been shown against AMD, DED possibly due its anti-inflammatory properties, these medications decrease pressure in IIH. Summary As usage increases, further dedicated safety trials are key determining eye-related complications. Given limited prospective available proven systemic benefits medication, well certain diseases, use should generally not discouraged most patients. Regular ophthalmologic follow up important patients considered at higher adverse events.
Language: Английский